Keratosis pilaris
diseaseOn this page
Also known as KP
Summary
Keratosis pilaris (MONDO:0021036) is a disease with 1 cohort gene and 8 clinical trials.
At a glance
- Cohort genes: 1
- ClinVar variants: 14
- Clinical trials: 8
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | keratosis pilaris |
| Mondo ID | MONDO:0021036 |
| ICD-11 | 1614890502 |
| NCIT | C124070 |
| SNOMED CT | 5132005 |
| UMLS | C0263383 |
| MedGen | 82664 |
| Is cancer (heuristic) | no |
Also known as: KP
Data availability: 14 ClinVar variants.
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › keratosis pilaris
Related subtypes (71): dermatitis, cutaneous mucinosis, skin neoplasm, pyoderma, chronic ulcer of skin, systemic sclerosis, sunburn, severe cutaneous adverse reaction, paronychia, Achenbach syndrome, erythema multiforme, erythematosquamous dermatosis, exanthem, facial dermatosis, hand dermatosis, keratosis, leg dermatosis, lichen disease, lipodystrophy, mongolian spot, reactive cutaneous fibrous lesion, rosacea, scalp dermatosis, sebaceous gland disorder, skin atrophy, skin sarcoidosis, sweat gland disorder, vesiculobullous skin disease, hyperglobulinemic purpura, ainhum, cheilitis glandularis, erythema palmare hereditarium, multiple benign circumferential skin creases on limbs, actinic prurigo, congenital lethal erythroderma, Parana hard-skin syndrome, Bazex-Dupre-Christol syndrome, nephrogenic systemic fibrosis, erosive pustular dermatosis of the scalp, pseudoxanthoma elasticum-like papillary dermal elastolysis, toxic dermatosis, oral erosive lichen, chronic actinic dermatitis, Jessner lymphocytic infiltration of the skin, acquired kinky hair syndrome, primary cutaneous plasmacytosis, cutaneous pseudolymphoma, corticosteroid-sensitive aseptic abscess syndrome, interstitial granulomatous dermatitis with arthritis, epidermal disease, skin pigmentation disorder, skin vascular disease, Wells syndrome, solar urticaria, pellagra, hereditary epidermal appendage anomaly, dermis disorder, aquagenic pruritus, Boudhina Yedes Khiari syndrome, non-neoplastic nevus, cutaneous sclerosis, pityriasis rotunda, hematohidrosis, skin disorder caused by infection, livedoid vasculopathy, prurigo nodularis, granuloma faciale, sclerema neonatorum, hereditary skin disorder, hand-foot syndrome, Nicolau syndrome
Subtypes (1): keratosis pilaris atrophicans
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
14 retrieved; paginated sample, class counts are floors:
12 benign, 1 pathogenic, 1 conflicting classifications of pathogenicity
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 132834 | NM_002332.3(LRP1):c.3734A>G (p.Lys1245Arg) | LRP1 | Pathogenic | no assertion criteria provided |
| 930178 | NM_002332.3(LRP1):c.300C>T (p.Asp100=) | LRP1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1222429 | NM_002332.3(LRP1):c.8574C>T (p.Cys2858=) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1226322 | NM_002332.3(LRP1):c.3546C>T (p.Cys1182=) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1236943 | NM_002332.3(LRP1):c.7278C>T (p.Ala2426=) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1252707 | NM_002332.3(LRP1):c.8893-7C>T | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1253715 | NM_002332.3(LRP1):c.8925C>T (p.Asp2975=) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1271847 | NM_002332.3(LRP1):c.8997T>C (p.Thr2999=) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1272520 | NM_002332.3(LRP1):c.8699A>C (p.Gln2900Pro) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1280360 | NM_002332.3(LRP1):c.8702-5C>T | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1282327 | NM_002332.3(LRP1):c.6842-22C>G | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1285717 | NM_002332.3(LRP1):c.9282+11C>T | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1297892 | NM_002332.3(LRP1):c.3793+25G>A | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
| 1300111 | NM_002332.3(LRP1):c.9783G>A (p.Thr3261=) | LRP1 | Benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 0 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| LRP1 | Orphanet:2340 | Keratosis follicularis spinulosa decalvans |
| LRP1 | Orphanet:79100 | Atrophoderma vermiculata |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| LRP1 | HGNC:6692 | ENSG00000123384 | Q07954 | Prolow-density lipoprotein receptor-related protein 1 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| LRP1 | Prolow-density lipoprotein receptor-related protein 1 | Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| LRP1 | Other/Unknown | no | LDLR_classB_rpt, EGF-type_Asp/Asn_hydroxyl_site, EGF |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| ascending aorta | 1 |
| descending thoracic aorta | 1 |
| stromal cell of endometrium | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| LRP1 | 293 | ubiquitous | marker | stromal cell of endometrium, descending thoracic aorta, ascending aorta |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| LRP1 | 2,662 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| LRP1 | Q07954 | 7 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 9. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Scavenging of heme from plasma | 1 | 878.5× | 0.007 | LRP1 |
| Binding and Uptake of Ligands by Scavenger Receptors | 1 | 543.8× | 0.007 | LRP1 |
| Metabolism of fat-soluble vitamins | 1 | 380.7× | 0.007 | LRP1 |
| Visual phototransduction | 1 | 259.6× | 0.007 | LRP1 |
| Retinoid metabolism and transport | 1 | 248.3× | 0.007 | LRP1 |
| Metabolism of vitamins and cofactors | 1 | 116.5× | 0.013 | LRP1 |
| Sensory Perception | 1 | 95.2× | 0.014 | LRP1 |
| Vesicle-mediated transport | 1 | 34.8× | 0.032 | LRP1 |
| Metabolism | 1 | 11.6× | 0.086 | LRP1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| positive regulation of transcytosis | 1 | 16852.0× | 0.001 | LRP1 |
| positive regulation of lipid transport | 1 | 8426.0× | 0.001 | LRP1 |
| positive regulation of reverse cholesterol transport | 1 | 8426.0× | 0.001 | LRP1 |
| astrocyte activation involved in immune response | 1 | 4213.0× | 0.001 | LRP1 |
| negative regulation of platelet-derived growth factor receptor-beta signaling pathway | 1 | 4213.0× | 0.001 | LRP1 |
| regulation of extracellular matrix disassembly | 1 | 3370.4× | 0.001 | LRP1 |
| positive regulation of lysosomal protein catabolic process | 1 | 3370.4× | 0.001 | LRP1 |
| amyloid-beta clearance by transcytosis | 1 | 2407.4× | 0.002 | LRP1 |
| amyloid-beta clearance by cellular catabolic process | 1 | 2106.5× | 0.002 | LRP1 |
| positive regulation of amyloid-beta clearance | 1 | 2106.5× | 0.002 | LRP1 |
| regulation of extracellular matrix organization | 1 | 1872.4× | 0.002 | LRP1 |
| transcytosis | 1 | 1685.2× | 0.002 | LRP1 |
| negative regulation of smooth muscle cell migration | 1 | 1532.0× | 0.002 | LRP1 |
| enzyme-linked receptor protein signaling pathway | 1 | 1296.3× | 0.002 | LRP1 |
| lipoprotein transport | 1 | 991.3× | 0.002 | LRP1 |
| amyloid-beta clearance | 1 | 936.2× | 0.002 | LRP1 |
| aorta morphogenesis | 1 | 887.0× | 0.002 | LRP1 |
| apoptotic cell clearance | 1 | 887.0× | 0.002 | LRP1 |
| positive regulation of endocytosis | 1 | 802.5× | 0.002 | LRP1 |
| lysosomal transport | 1 | 702.2× | 0.002 | LRP1 |
| positive regulation of cholesterol efflux | 1 | 624.1× | 0.002 | LRP1 |
| negative regulation of SMAD protein signal transduction | 1 | 601.9× | 0.002 | LRP1 |
| retinoid metabolic process | 1 | 495.6× | 0.003 | LRP1 |
| cellular response to amyloid-beta | 1 | 391.9× | 0.004 | LRP1 |
| negative regulation of Wnt signaling pathway | 1 | 343.9× | 0.004 | LRP1 |
| receptor internalization | 1 | 324.1× | 0.004 | LRP1 |
| positive regulation of protein localization to plasma membrane | 1 | 271.8× | 0.004 | LRP1 |
| phagocytosis | 1 | 240.7× | 0.005 | LRP1 |
| receptor-mediated endocytosis | 1 | 221.7× | 0.005 | LRP1 |
| transport across blood-brain barrier | 1 | 179.3× | 0.006 | LRP1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| LRP1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | LRP1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| LRP1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 8.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 6 |
| PHASE4 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00944216 | PHASE4 | TERMINATED | Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study |
| NCT04797663 | PHASE4 | COMPLETED | Long-pulsed 1064 nm Nd-YAG Laser Versus TCA 20% in Treatment of Keratosis Pilaris |
| NCT07078461 | Not specified | RECRUITING | Investigating the Safety and Efficacy of the 1927-nm Thulium Laser in Keratosis Pilaris |
| NCT01281644 | Not specified | COMPLETED | Treatment of Keratosis Pilaris With 810 nm Diode Laser |
| NCT03243617 | Not specified | COMPLETED | Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris |
| NCT05535517 | Not specified | UNKNOWN | Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris |
| NCT05666011 | Not specified | UNKNOWN | Laser to Aid in Treatment of Keratosis Pilaris on Arms |
| NCT06032078 | Not specified | UNKNOWN | Evaluation of the Responsiveness of Investigator Global Assessment Score for Keratosis Pilaris |
Related Atlas pages
- Cohort genes: LRP1